Compare Dow Inc (DOW) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs GSK plc — how do they compare? Dow Inc trades at $28.8 (market cap $20.65B), while GSK plc trades at $46.65 (market cap $91.88B). The key difference: GSK plc is far larger — about 4.4× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and GSK plc for 93 Days on average.
| DOW | GSK | |
|---|---|---|
Market Cap | $20.65B | $91.88B |
Volume | 14,126,943 | 7,730,529 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $61.18 |
52-Week Low | $20.65 | $43.24 |
Typical Hold Time | 82 Days | 93 Days |
Enterprise Value | $36.34B | $111.88B |
Dividend Yield | 4.9% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.80, up 3.71% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite negative profitability, with ROE at -7.86% and net income margin at -3.13%. Recent earnings have beaten expectations, but revenue declined to $39.97B in 2025. Cash flow improved to $1.69B net in 2025, though operating cash flow remains pressured.
Outlook is mixed: analyst consensus is a hold with a $34.22 price target, implying 19% upside, but weak margins and declining revenue pose risks. The dividend yield offers income support, but investors face headwinds from cyclical chemical demand and high debt levels, with debt-to-asset ratio rising to 29.87% in 2025.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
